Teriflunomide in MS: TEMSO extension data


REPORT FROM THE 25TH CONGRESS OF THE EUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS (ECTRIMS) – AMSTERDAM, THE NETHERLANDS, OCTOBER 19-22, 2011 – The TEMSO phase III trial reported that oral teriflunomide 7 mg or 14 mg significantly reduced the annualized relapse rate compared to placebo (0.37 for either dose vs. 0.57; relative risk reduction 31%) (O’Connor et al. N Engl J Med 2011; 365: 1293-1303).

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page